+49 (0)5251 / 3903215 | info@eurumed.de
Eu-Ru Med

Bring your patients into acid-base balance

The acid-base balance is still a shadowy existence in medicine. The problem is generally only known to naturopathic therapists. Otherwise, acid-base diagnosis and therapy – apart from intensive care units – is only carried out by a few specialized practices. Accordingly, the topic hardly finds its way into conventional therapy schemes – to the disadvantage of many chronically ill patients.

For the strictly conventional medical group, the diagnosis and therapy of the acid-base ratios are reserved for clinical medicine and usually intensive care, and are therefore linked to serious and lifethreatening diseases. The term chronic latent acidosis or tissue acidosis practically does not exist here.

The method of blood pH measurement used in clinical medicine is unsuitable for assessing tissue acidosis, because ultimately the user’s measuring probe does not allow access to the intracellular situation. Practical experience with many different clinical pictures confirms the importance of intracellular acidification and so naturopathic practices are now able to use proven diagnostic and therapeutic options.

Our company

The Eu-Ru Med GmbH was founded 1997 by Peter Ruland. With the Eu-Ru Bibag infusion bag set for the production of a mixed infusion (procaine-) base infusion, backed up with stability data, it was now possible for the first time to offer a highly alkaline solution, such as 8.4% sodium hydrogen carbonate in a practical infusion bag. Procaine base infusion has become established in neural therapy and cannot be replaced both in the treatment of pain and in complementary tumour therapy. The finished infusion bag system with coordinated application technology also increases safety by optimizing the hygienic aspects, i.e. less risk of contamination.

In 2007 the pH buffer capacity measurement of the buffer capacity and the calculation of the intracellular acidosis could now be carried out with the Jörgensen blood titration in a small laboratory.

At Four 20  Pharma GmbH as manufacturer, pharmaceutical entrepreneur and importer for medical cannabis, the patient and his pain are also in focus. In the “pain pyramid” at the top, cannabis can stimulate the “resistant opiate receptors” through long term treatments. Medical cannabis can be an alternative to opiates with less side effects.

Activation and improvement of the basic regulation – by relaxation and relaxation of pain states (also by nerve diseases) are the further additional therapeutic approaches. Because painkillers from the group of NSAIDs such as ibuprofen, diclofenac or ASA are generally less indicated here. The therapy approaches of both companies complement each other in the pain environment.

We look forward to working with you and will be happy to answer any questions you may have.

Eu-Ru Med